Cepheid, Danaher's molecular diagnostics business, is cutting 67 jobs at its Sunnyvale, California site. A WARN notice filed with the state puts the effective date at December 28 and says most of those affected are scientists and engineers. Five work remotely. A company representative called the cuts part of regular business planning.
The reductions follow a long contraction at the site. Cepheid told California last year it planned to cut 167 positions across the state, and it laid off more than 1,300 people in California in 2023 and 2024 as respiratory test volumes fell after the pandemic. Danaher bought Cepheid in 2016 for about $4 billion and projects flat core diagnostics revenue growth for fiscal 2026 excluding respiratory testing, after 1.5 percent in 2025.
Sunnyvale R&D headcount is where a diagnostics business decides how many new assays it intends to develop. Cutting scientists and engineers points to a narrower menu ahead.